Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival?

被引:272
作者
Chen, H [1 ]
Hardacre, JM [1 ]
Uzar, A [1 ]
Cameron, JL [1 ]
Choti, MA [1 ]
机构
[1] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA
关键词
D O I
10.1016/S1072-7515(98)00099-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Neuroendocrine tumors commonly metastasize to the liver. Although surgical resection is considered a treatment option for patients with localized metastases confined to the liver, the longterm survival benefit of liver resection has not been clearly demonstrated. We examined the survival of patients undergoing liver resection for this disease. Study Design: Between 1984 and 1995, we evaluated 38 patients with liver-only metastases from neuroendocrine tumors, including 21 carcinoid, 13 islet cell, and 4 atypical neuroendocrine neoplasms. Data from a combined prospective and retrospective database and a tumor registry were analyzed. Of these patients, 15 underwent complete resection of all known disease. The remaining 23 patients, who also had disease confined to the liver, had comparable tumor burden but were believed to be unresectable. The longterm survival rates of these two groups were compared. Results: Patients who underwent Liver resection did not differ from chose who were unresectable with regard to age, pathology primary tumor site, serum alkaline phosphatase levels, or percentage of the liver involved. All resections were complete, leaving no residual disease, and consisted of lobectomy (n = 3), segmentectomy (n = 1), and wedge resections (n = 11), There were no operative deaths. Patients who underwent hepatic resection had a significantly longer survival than unresected patients. Although median survival had not been reached in resected patients, the median survival in the unresectable group was 27 months. Patients who underwent liver resection had a higher 5-year actuarial survival (73% versus 29%). Conclusions: Hepatic resection in selected patients with isolated liver metastases from meuroendocrine tumors may prolong survival. This conclusion was reached by comparing our resected group with an unresectable group with similar tumor burden. (J Am Cell Surg 1998;187:88-93. (C) 1998 by the American College of Surgeons).
引用
收藏
页码:88 / 92
页数:5
相关论文
共 29 条
  • [1] BERGE T, 1976, ACTA PATH MICRO IM A, V84, P322
  • [2] COZZI PJ, 1995, CANCER, V76, P501, DOI 10.1002/1097-0142(19950801)76:3<501::AID-CNCR2820760322>3.0.CO
  • [3] 2-X
  • [4] DECLORE R, 1994, J AM COLL SURGEONS, V178, P188
  • [5] Metastatic endocrine tumors: Medical treatment, surgical resection, or liver transplantation
    Dousset, B
    SaintMarc, O
    Pitre, J
    Soubrane, O
    Houssin, D
    Chapuis, Y
    [J]. WORLD JOURNAL OF SURGERY, 1996, 20 (07) : 908 - 915
  • [6] GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO
  • [7] 2-4
  • [8] EFFECTIVE PALLIATIVE TREATMENT OF METASTATIC CARCINOID-TUMORS WITH INTRAARTERIAL CHEMOTHERAPY CHEMOEMBOLIZATION COMBINED WITH OCTREOTIDE ACETATE
    HAJARIZADEH, H
    IVANCEV, K
    MUELLER, CR
    FLETCHER, WS
    WOLTERING, EA
    [J]. AMERICAN JOURNAL OF SURGERY, 1992, 163 (05) : 479 - 483
  • [9] HUGHES KS, 1986, SURGERY, V100, P278
  • [10] CLINICAL EFFECTS OF OCTREOTIDE COMPARED TO PLACEBO IN PATIENTS WITH GASTROINTESTINAL NEUROENDOCRINE TUMORS - REPORT ON A DOUBLE-BLIND, RANDOMIZED TRIAL
    JACOBSEN, MB
    HANSSEN, LE
    [J]. JOURNAL OF INTERNAL MEDICINE, 1995, 237 (03) : 269 - 275